(UNDATED) - The Food and Drug Administration has approved a diabetes drug created in a collaborative effort between Eli Lilly and Connecticut-based Boehringer Ingelheim Pharmaceuticals.
Tradjenta lowers blood sugar in a glucose-dependent manner by increasing incretin levels.
The drug is approved to be used by people with type 2 diabetes in conjunction with diet and exercise.
Have a question or comment about a news story? Send it to email@example.com